Publications by authors named "Lisa Hammond"

Claim this Profile
F
Factors affecting the advancement of Black nurses into leadership roles: A scoping review.
Yolanda M Nelson, Jawanza Bundy, Elissa Harmon, Lisa Hammond, Karima Robinson

Nurs Outlook· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pain control using liposomal bupivacaine versus bupivacaine for robotic assisted thoracic surgery.
Molly Rincavage, Lisa Hammond, Shalini Reddy, Christine Sytsma, Amanda Prater

Int J Clin Pharm· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of timing of trastuzumab initiation on long-term outcome of patients with early-stage HER2-positive breast cancer: the "one thousand HER2 patients" project.
Giuseppe Gullo, Naomi Walsh, David Fennelly, Reetesh Bose, Janice Walshe, Lisa Hammond

Br J Cancer· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Asymmetric cyclopropanation of conjugated cyanosulfones using a novel cupreine organocatalyst: rapid access to δ(3)-amino acids.
Lewis S Aitken, Lisa E Hammond, Rajkumar Sundaram, Kenneth Shankland, Geoffrey D Brown

Chem Commun (Camb)· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of genes involved in Pseudomonas aeruginosa biofilm-specific resistance to antibiotics.
Li Zhang, Meredith Fritsch, Lisa Hammond, Ryan Landreville, Cristina Slatculescu

PLoS One· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of risks associated with the prescribing and dispensing of oral anticancer medicines in Ireland.
Lisa Hammond, Elaine Marsden, Niamh O'Hanlon, Fionnuala King, Martin Charles Henman

Int J Clin Pharm· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study.
Jordi Rodon, Mitchell Garrison, Lisa A Hammond, Johann de Bono, Lon Smith

Cancer Chemother Pharmacol· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma.
Monica M Mita, Eric K Rowinsky, Leonardo Forero, S Gail Eckhart, Elzbieta Izbicka, Lisa A Hammond

Cancer Chemother Pharmacol· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I and pharmacokinetic study of pemetrexed plus irinotecan in patients with advanced solid malignancies.
Eric K Rowinsky, Muralidhar Beeram, Lisa A Hammond, Garry Schwartz, Johann De Bono

Clin Cancer Res· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I, pharmacokinetic, and biological study of erlotinib in combination with paclitaxel and carboplatin in patients with advanced solid tumors.
Amita Patnaik, Debra Wood, Anthony W Tolcher, Marta Hamilton, Jeffrey I Kreisberg, Lisa A Hammond

Clin Cancer Res· December 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I and pharmacokinetic study of tasidotin hydrochloride (ILX651), a third-generation dolastatin-15 analogue, administered weekly for 3 weeks every 28 days in patients with advanced solid tumors.
Alain C Mita, Lisa A Hammond, Peter L Bonate, Geoffrey Weiss, Heather McCreery

Clin Cancer Res· September 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 and pharmacokinetic study of intravenous irinotecan in refractory solid tumor patients with hepatic dysfunction.
Larry J Schaaf, Lisa A Hammond, Stuart J Tipping, Richard M Goldberg, Rakesh Goel

Clin Cancer Res· June 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I, pharmacokinetic, and pharmacodynamic study of intravenously administered Ad5CMV-p53, an adenoviral vector containing the wild-type p53 gene, in patients with advanced cancer.
Anthony W Tolcher, Desiree Hao, Johann de Bono, Alex Miller, Amita Patnaik, Lisa A Hammond

J Clin Oncol· May 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function.
Alain C Mita, Christopher J Sweeney, Sharyn D Baker, Andrew Goetz, Lisa A Hammond

J Clin Oncol· February 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I and pharmacokinetic study of sequences of the rebeccamycin analogue NSC 655649 and cisplatin in patients with advanced solid tumors.
Alejandro D Ricart, Lisa A Hammond, John G Kuhn, Chris H Takimoto, Andrew Goetz

Clin Cancer Res· December 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously daily for 5 consecutive days every 3 weeks in patients with advanced solid tumors.
Scot Ebbinghaus, Eric Rubin, Evan Hersh, Lee D Cranmer, Peter L Bonate, Lisa A Hammond

Clin Cancer Res· November 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I and pharmacokinetic study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously on days 1, 3, and 5 every 3 weeks in patients with advanced solid tumors.
Casey Cunningham, Leonard J Appleman, Miora Kirvan-Visovatti, David P Ryan, Eileen Regan, Lisa A Hammond

Clin Cancer Res· November 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FGF-21 as a novel metabolic regulator.
Alexei Kharitonenkov, Tatiyana L Shiyanova, Anja Koester, Amy M Ford, Radmila Micanovic, Lisa J Hammond

J Clin Invest· June 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Administration of CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, is feasible on a 7-day on, 7-day off schedule: a phase I pharmacokinetic and food effect study.
Emiliano Calvo, Anthony W Tolcher, Lisa A Hammond, Amita Patnaik, Johan S de Bono

Clin Cancer Res· November 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
ING-1, a monoclonal antibody targeting Ep-CAM in patients with advanced adenocarcinomas.
Johann S de Bono, Anthony W Tolcher, Andre Forero, Gertrude F A Vanhove, Chris Takimoto, Lisa A Hammond

Clin Cancer Res· November 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I and pharmacokinetic study of Col-3 (Metastat), an oral tetracycline derivative with potent matrix metalloproteinase and antitumor properties.
Samira Syed, Chris Takimoto, Manuel Hidalgo, Jinee Rizzo, John G Kuhn, Lisa A Hammond

Clin Cancer Res· October 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies.
Quincy Siu-Chung Chu, Lisa A Hammond, Garry Schwartz, Leonel Ochoa, Sun-Young Rha

Clin Cancer Res· August 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer.
Anthony W Tolcher, John Kuhn, Garry Schwartz, Amita Patnaik, Lisa A Hammond

Clin Cancer Res· August 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer.
Román Pérez-Soler, Abraham Chachoua, Lisa A Hammond, Eric K Rowinsky, Mark Huberman

J Clin Oncol· August 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acute retinal toxicity from the novel anti-tumor agent, Irofulven.
Robert F Melendez, Joseph M Harrison, Eric K Rowinsky, Lisa A Hammond, Thomas D Fitzsimmons

Doc Ophthalmol· May 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis